| Full text | |
| Author(s): |
Tanaka-Azevedo, A. M.
;
Morais-Zani, K.
;
Torquato, R. J. S.
;
Tanaka, A. S.
Total Authors: 4
|
| Document type: | Journal article |
| Source: | JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY; v. N/A, p. 9-pg., 2010-01-01. |
| Abstract | |
Venous and arterial thromboembolic diseases are still the most frequent causes of death and disability in high-income countries. Clinical anticoagulants are inhibitors of enzymes involved in the coagulation pathway, such as thrombin and factor Xa. Thrombin is a key enzyme of blood coagulation system, activating the platelets, converting the fibrinogen to the fibrin net, and amplifying its self-generation by the activation of factors V, VIII, and XI. Thrombin has long been a target for the development of oral anticoagulants. Furthermore, selective inhibitors of thrombin represent a new class of antithrombotic agents. For these reasons, a number of specific thrombin inhibitors are under evaluation for possible use as antithrombotic drugs. This paper summarizes old and new interests of specific thrombin inhibitors described in different animals. (AU) | |
| FAPESP's process: | 10/51659-4 - Thrombin inhibitors from different animals |
| Grantee: | Anita Mitico Tanaka-Azevedo |
| Support Opportunities: | Regular Research Grants - Publications - Scientific article |